title: Effect of diclofenac sodium combined with nuclear rotation on the prevention of posterior capsule opacification: two-year follow-up.
abstract: OBJECTIVE
  To evaluate the effect of combined diclofenac sodium and nuclear rotation on the prevention of posterior capsule opacification (PCO).
  
  
  METHODS
  Wuxi People's Hospital, Jiangsu, China.
  
  
  METHODS
  Comparative case series.
  
  
  METHODS
  In a preclinical trial, porcine eyes were randomized to have hydrodissection with diclofenac sodium (Group A), diclofenac sodium and nuclear rotation (Group B), or a control (balanced salt solution/lidocaine). Primary cells of porcine lens epithelium from the posterior lens capsule were obtained in each group. Proliferation and coverage time for lens epithelial cells (LECs) were noted. In the clinical study, patients with age-related cataract were divided into 4 groups. Hydrodissection was performed with a balanced salt solution in Group 1, with lidocaine in Group 2, with 0.25 mg/mL diclofenac sodium in Group 3, and with 0.25 mg/mL combined diclofenac sodium and nuclear rotation in Group 4. Visual acuity and corneal endothelial cell density (ECD) were measured.
  
  
  RESULTS
  In the preclinical trial (n = 30), the LEC coverage time in Group A and Group B was significantly longer than in the control group (P<.001). In the clinical study (n = 72), there were no significant differences between the 4 groups in corrected distance visual acuity or corneal ECD during the 2-year follow-up (P>.05). The PCO scores in Groups 3 and 4 were significantly lower than in Groups 1 and 2 (χ(2) = 23.109, P<.001). The lowest PCO score was in Group 4.
  
  
  CONCLUSIONS
  Hydrodissection using combined diclofenac sodium and nuclear rotation prevented PCO up to 2 years postoperatively.
  
  
  BACKGROUND
  No author has a financial or proprietary interest in any material or method mentioned.
authors.affiliation: Departments of Ophthalmology, Wuxi People's Hospital, Jiangsu, People's Republic of China. pard1@126.com
authors.forename: Yong
authors.initials: Y
authors.lastname: Yao
authors.forename: Jun
authors.initials: J
authors.lastname: Shao
authors.forename: Xuhua
authors.initials: X
authors.lastname: Tan
authors.forename: Huiyan
authors.initials: H
authors.lastname: Xu
authors.forename: Weiping
authors.initials: W
authors.lastname: Hu
authors.forename: Hongyu
authors.initials: H
authors.lastname: Huang
authors.forename: Ying
authors.initials: Y
authors.lastname: Cai
authors.forename: Lixia
authors.initials: L
authors.lastname: Liu
mesh_terms: D000368:Aged; D000818:Animals; D000894:Anti-Inflammatory Agents, Non-Steroidal / Q000008:administration & dosage* / Q000494:pharmacology; D058442:Capsule Opacification / Q000517:prevention & control*; D002452:Cell Count; D049109:Cell Proliferation / Q000187:drug effects; D004008:Diclofenac / Q000008:administration & dosage* / Q000494:pharmacology; D004847:Epithelial Cells / Q000187:drug effects; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D019654:Lens Implantation, Intraocular; D007907:Lens Nucleus, Crystalline; D007908:Lens, Crystalline / Q000166:cytology; D008297:Male; D008875:Middle Aged; D018918:Phacoemulsification; D012399:Rotation; D013552:Swine; D014792:Visual Acuity / Q000502:physiology
chemical_list: D000894:Anti-Inflammatory Agents, Non-Steroidal; D004008:Diclofenac